Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by Jesus4Prezon Jun 02, 2020 11:52pm

233 Views

Post# 31104903

FDA Permanent Changes to Protocols

Hey All,

Never posted here before, but just read a great article about permanent changes to protocols regarding drug approval processes at FDA. This article suggests Covid has given the FDA reason to remove unnecessary barriers to drug approvals going forward. This is the kind of stuff that could help RVX greatly.

https://www.fiercebiotech.com/biotech/hahn-permanently-adopting-r-d-accelerating-covid-19-measures-a-top-fda-priority

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading